We are live on
!
Find out more
AAA
Affinity Asset Advisors Portfolio holdings
AUM
$1.94B
1-Year Est. Return
374.45%
This Fund
S&P 500
This Quarter
Est. Return
+59.91%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$255M
AUM Growth
-$103M
(-29%)
Cap. Flow
-$140M
Cap. Flow
% of AUM
-54.73%
Top 10 Holdings %
Top 10 Hldgs %
45.35%
Holding
89
New
26
Increased
17
Reduced
12
Closed
26
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioMarin Pharmaceuticals
BMRN
|
+$7.51M |
| 2 |
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
+$6.07M |
| 3 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$3.74M |
| 4 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
+$3.67M |
| 5 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
+$3.24M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$12.9M |
| 2 |
Sanofi
SNY
|
+$11.4M |
| 3 |
Establishment Labs
ESTA
|
+$8.21M |
| 4 |
Kura Oncology
KURA
|
+$5.92M |
| 5 |
AstraZeneca
AZN
|
+$5.64M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 81.4% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SWTX
76
DELISTED
SpringWorks Therapeutics
SWTX
| – | – |
-175,000
| Closed | -$4.99M |
|
77
Tango Therapeutics
TNGX
$4.38B
| – | – |
-81,982
| Closed | -$297K |
|
|
VERV
78
CALL
DELISTED
Verve Therapeutics
VERV
| – | – |
-20,000
| Closed | -$687K |
|
|
VRNA
79
PUT
DELISTED
Verona Pharma
VRNA
| – | – |
-165,100
| Closed | -$1.69M |
|
80
Zentalis Pharmaceuticals
ZNTL
$304M
| – | – |
-170,000
| Closed | -$3.68M |
|
|
ARYE
81
DELISTED
ARYA Sciences Acquisition Corp V Class A Ordinary Shares
ARYE
| – | – |
-352,500
| Closed | -$3.46M |
|
|
ISEE
82
CALL
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| – | – |
-30,000
| Closed | -$538K |
|
|
RCOR.WS
83
DELISTED
Renovacor, Inc. Warrants, entitling the holder thereof to purchase one-half (1/2) of a share of common stock at a price of $11. 50 per whole share
RCOR.WS
| – | – |
-75,000
| Closed | -$6K |
|
|
RCOR
84
DELISTED
Renovacor, Inc.
RCOR
| – | – |
-199,490
| Closed | -$503K |
|
|
GBT
85
DELISTED
Global Blood Therapeutics, Inc.
GBT
| – | – |
-190,000
| Closed | -$12.9M |
|
Similar funds
FM
1SB
HCL
OCM
MWA
HC
FFH
BC
Affinity Asset Advisors's Q4 2022 Portfolio in Review
As of Q4 2022, Affinity Asset Advisors held 89 positions worth $255M, down 29% from $358M the previous quarter. Its ten largest holdings account for 45% of the portfolio.
Affinity Asset Advisors withdrew a net $140M in Q4 2022, closing 26 positions and reducing 12 holdings. Its most notable exit was Global Blood Therapeutics, Inc., an estimated $12.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 81% of assets, up from 51% a quarter earlier, followed by Financials.
Against the trend, Affinity Asset Advisors opened a new position in BioMarin Pharmaceuticals worth $8.28M.
- Affinity Asset Advisors's largest Q4 2022 buy was BioMarin Pharmaceuticals: 80,000 shares worth $8.28M.
- Affinity Asset Advisors added most to Morphic Holding, Inc. Common Stock in Q4 2022, an estimated $3.67M increase.
- Affinity Asset Advisors's biggest Q4 2022 reduction was Establishment Labs, cutting an estimated $8.21M.
- Affinity Asset Advisors fully exited Global Blood Therapeutics, Inc. in Q4 2022, selling an estimated $12.9M.
- Affinity Asset Advisors's ten largest holdings make up 45% of its $255M portfolio in Q4 2022.
- Affinity Asset Advisors opened 26 new positions and closed 26 in Q4 2022.
- Affinity Asset Advisors's portfolio value fell 29% quarter-over-quarter to $255M.
Based on Affinity Asset Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.